Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.

about

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.

Item

http://www.wikidata.org/entity/Q55347421

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@en

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@nl

type

Item

label

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@en

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@nl

prefLabel

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@en

Sucroferric oxyhydroxide decre ...... emia in hemodialysis patients.

@nl

P1476

Sucroferric oxyhydroxide decre ...... nemia in hemodialysis patients

@en

P2093

Jun Minakuchi

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Okada

http://www.w3.org/2001/XMLSchema#string

Keiko Miya

http://www.w3.org/2001/XMLSchema#string

Shu Kawashima

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis).

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients.

Phosphorus binders and survival on hemodialysis.

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

P2888

s13104-018-3483-6

P304

363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-018-3483-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hisato Shima

P577

2018-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104481231

http://www.w3.org/2001/XMLSchema#string

P698

29884226

http://www.w3.org/2001/XMLSchema#string

P932

5994086

http://www.w3.org/2001/XMLSchema#string